Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.

Protagenic Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FINDINGS SUPPORT ADVANCEMENT INTO PHASE 2 TO EXPLORE A FIRST-IN-CLASS PATHWAY AIMED AT STRESS-RELATED NEUROPSYCHIATRIC CONDITIONS NEW YORK CITY, NEW YORK / ACCESS NEWSWIRE / DECEMBER 9, 2025 / PROTAGENIC THERAPEUTICS INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING THERAPEUTICS THAT TARGET THE BIOLOGY OF CHRONIC STRESS AND ITS DOWNSTREAM PSYCHIATRIC AND NEUROLOGIC EFFECTS, TODAY REPORTED POSITIVE TOPLINE SAFETY RESULTS FROM ITS PHASE 1 MULTIPLE DOSE (MD) STUDY OF PT00114. PT00114 IS A SYNTHETIC ANALOGUE OF A NATURALLY OCCURRING BRAIN PEPTIDE THOUGHT TO BE INVOLVED IN RESTORING HOMEOSTASIS FOLLOWING PROLONGED EXPOSURE TO STRESS.

RESULTS FROM PHASE 1 MULTIPLE-DOSE STUDY OF PT00114

NEW YORK, NY / ACCESS NEWSWIRE / NOVEMBER 27, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") TODAY ANNOUNCED THAT IT HAS RECEIVED A NOTIFICATION LETTER FROM THE NASDAQ LISTING QUALIFICATIONS STAFF (THE "STAFF") INDICATING THAT THE COMPANY IS NOT IN COMPLIANCE WITH NASDAQ LISTING RULES 5550(B)(1) (MINIMUM STOCKHOLDERS' EQUITY) AND 5250(C)(1) (TIMELY FILING OF PERIODIC REPORTS). THE STAFF DETERMINED THAT, BASED ON THE STOCKHOLDERS' EQUITY REPORTED IN THE COMPANY'S TRANSITION REPORT ON FORM 10-QT FOR THE PERIOD ENDED JUNE 30, 2025, THE COMPANY NO LONGER SATISFIES THE MINIMUM $2.5 MILLION STOCKHOLDERS' EQUITY REQUIREMENT UNDER LISTING RULE 5550(B)(1).

PROTAGENIC THERAPEUTICS ANNOUNCES RECEIPT OF NASDAQ NON-COMPLIANCE NOTICE

NEW YORK CITY, NY / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / PROTAGENIC THERAPEUTICS INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR STRESS-RELATED NEUROPSYCHIATRIC AND NEURODEGENERATIVE DISORDERS, TODAY ANNOUNCED THE SUCCESSFUL COMPLETION OF ENROLLMENT AND DOSING IN ITS MULTIPLE ASCENDING DOSE (MAD) PHASE 1 STUDY EVALUATING ITS LEAD COMPOUND, KNOWN AS PT00114. THE STUDY, CONDUCTED IN HEALTHY VOLUNTEERS, WAS DESIGNED TO ASSESS THE SAFETY AND TOLERABILITY PROFILE OF PT00114 FOLLOWING MULTIPLE DOSES OVER TIME.

PROTAGENIC THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT AND DOSING IN PHASE 1 MAD STUDY

DELAY ATTRIBUTABLE TO MERGER-RELATED FINANCIAL CONSOLIDATION NEW YORK, NY / ACCESS NEWSWIRE / AUGUST 22, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL NEURO-ACTIVE PEPTIDE THERAPIES, TODAY ANNOUNCED THAT IT EXPECTS TO FILE ITS QUARTERLY REPORT ON FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2025 IN THE NEAR FUTURE, FOLLOWING A DELAY ATTRIBUTABLE TO THE COMPLETION OF MERGER-RELATED CONSOLIDATION OF FINANCIAL STATEMENTS, INCLUDING PURCHASE ACCOUNTING ADJUSTMENTS, PRO FORMA FINANCIAL INFORMATION, AND RELATED DISCLOSURES. WHILE THE COMPANY ANTICIPATES THIS DELAY TO BE BRIEF, THERE CAN BE NO ASSURANCE AS TO THE DEFINITIVE TIMING OF THE FILING.

PROTAGENIC THERAPEUTICS PROVIDES UPDATE ON FORM 10-Q FILING TIMELINE AND NASDAQ COMPLIANCE

DOSING COMPLETION EXPECTED BY END OF AUGUST; PHASE 2 TRIAL EXPECTED TO BEGIN IN 1Q 2026 NEW YORK, NY / ACCESS NEWSWIRE / AUGUST 21, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX), A BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL NEURO-ACTIVE PEPTIDE THERAPIES, TODAY ANNOUNCED COMPLETION OF FIRST DOSE INJECTION FOR ALL STUDY SUBJECTS IN THE MULTIPLE-DOSE PORTION OF ITS ONGOING PHASE I CLINICAL TRIAL OF PT00114. THE COMPANY EXPECTS TO COMPLETE DOSING BY THE END OF AUGUST, WITH TOPLINE SAFETY DATA ANTICIPATED BY THE END OF SEPTEMBER, SUPPORTING ADVANCEMENT INTO PHASE 2 EFFICACY STUDIES PLANNED FOR THE FIRST QUARTER OF 2026.

PROTAGENIC THERAPEUTICS ADVANCES PT00114 INTO MULTIPLE-DOSE PHASE 1 TRIAL; POSITIONING FOR PHASE 2 IN STRESS & MOOD DISORDERS

NEW YORK, NY AND SANTA BARBARA, CA, JULY 30, 2025  PRISM MEDIAWIRE  PROTAGENIC THERAPEUTICS, INC. (NASDAQ: PTIX) (THE COMPANY) TODAY ANNOUNCES THAT ON JULY 18, 2025, THE JAPANESE PATENT OFFICE GRANTED PATENT JP 7714571B, A PATENT WHICH RUNS UNTIL MARCH 31, 2041.

PROTAGENIC THERAPEUTICS ANNOUNCES GRANT OF NEW PATENT IN JAPAN FOR ITS MODIFIED STILBENOID PROGRAM DRUG CANDIDATES

NEW YORK AND SANTA BARBARA, CALIF., JULY 30, 2025 (GLOBE NEWSWIRE) -- PROTAGENIC THERAPEUTICS, INC. (NASDAQ: PTIX) (THE COMPANY) TODAY ANNOUNCES THAT ON JULY 18, 2025, THE JAPANESE PATENT OFFICE GRANTED PATENT JP 7714571B, A PATENT WHICH RUNS UNTIL MARCH 31, 2041.

NEW YORK, NY / ACCESS NEWSWIRE / MAY 21, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") ANNOUNCED TODAY THAT WARRANT EXCHANGES AND EXERCISES OVER THE LAST FOUR TRADING DAYS HAVE GENERATED $3.1 MILLION IN CASH. THE PROCEEDS WILL FUND WORKING-CAPITAL NEEDS AND ADVANCE THE COMPANY'S PEPTIDE-BASED DRUG CANDIDATES FOR STRESS-RELATED AND CENTRAL-NERVOUS-SYSTEM DISORDERS.

PROTAGENIC THERAPEUTICS RECEIVES $3.1 MILLION FROM RECENT WARRANT ACTIVITY

NEW YORK, NY AND SANTA BARBARA, CA / ACCESS NEWSWIRE / MAY 19, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) (THE "COMPANY") AND PHYTANIX BIO INC. HAVE ENTERED INTO A DEFINITIVE SHARE EXCHANGE AGREEMENT PURSUANT TO WHICH THE TWO ENTITIES WILL COMBINE IN AN ALL-STOCK TRANSACTION (THE "COMBINATION"). THE COMBINED ENTITY, TO BE CALLED PHYTANIX, INC., WILL BRING TOGETHER TWO PIPELINES FOCUSED ON STRESS-RELATED AND CNS DISORDERS, FIVE PRECLINICAL ASSETS AND ONE CLINICAL-STAGE ASSET.

PROTAGENIC THERAPEUTICS AND PHYTANIX ANNOUNCE BUSINESS COMBINATION TO FORM NEUROACTIVE BIOPHARMACEUTICAL COMPANY WITH SIX DRUG CANDIDATES IN DEVELOPMENT INCLUDING TREATMENTS FOR OBESITY AND METABOLIC DISORDERS

MEASURE TAKEN TO COMPLY WITH NASDAQ RULE 5550(A)(2) REGARDING MINIMUM BID PRICE NEW YORK, NY / ACCESS NEWSWIRE / APRIL 29, 2025 / PROTAGENIC THERAPEUTICS, INC. (NASDAQ:PTIX) ("PROTAGENIC THERAPEUTICS" OR THE "COMPANY"), A LEADER IN BIOPHARMACEUTICAL INNOVATION, TODAY ANNOUNCED THAT THE COMPANY'S BOARD OF DIRECTORS HAS APPROVED A 1-FOR-14 REVERSE STOCK SPLIT OF THE COMPANY'S ISSUED AND OUTSTANDING COMMON STOCK, PAR VALUE $0.0001 PER SHARE (THE "COMMON STOCK") TO BE EFFECTIVE 12:01 A.M., EASTERN TIME, ON MAY 5, 2025.

Protagenic Therapeutics, Inc.

PTIX

Price

Financial Reports

No items found.

Press Releases

Protagenic Therapeutics, Inc.

PTIX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PTIX